1. Home
  2. BBY vs ALNY Comparison

BBY vs ALNY Comparison

Compare BBY & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Best Buy Co. Inc.

BBY

Best Buy Co. Inc.

N/A

Current Price

$101.23

Market Cap

18.2B

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$156.94

Market Cap

21.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BBY
ALNY
Founded
1966
2002
Country
United States
United States
Employees
N/A
115
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.2B
21.6B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
BBY
ALNY
Price
$101.23
$156.94
Analyst Decision
Hold
Buy
Analyst Count
25
30
Target Price
$87.85
★ $302.48
AVG Volume (30 Days)
★ 2.8M
2.5M
Earning Date
11-24-2026
10-29-2026
Dividend Yield
★ 3.86%
N/A
EPS Growth
17.76
★ 206.88
EPS
2.79
★ 18.42
Revenue
★ $41,691,000,000.00
$1,037,418,000.00
Revenue This Year
$2.34
$46.44
Revenue Next Year
$1.67
$20.78
P/E Ratio
$36.33
★ $8.74
Revenue Growth
0.39
★ 22.88
52 Week Low
$55.10
$156.00
52 Week High
$101.49
$479.79

Technical Indicators

Market Signals
Indicator
BBY
ALNY
Relative Strength Index (RSI) 60.52 21.96
Support Level $59.52 N/A
Resistance Level N/A $237.47
Average True Range (ATR) 3.54 10.24
MACD 0.27 -6.26
Stochastic Oscillator 79.44 2.62

Price Performance

Historical Comparison
BBY
ALNY

About BBY Best Buy Co. Inc.

Best Buy Co Inc is a pure-play consumer electronics retailer in the USA. It has two reportable segments: Domestic and International. The Domestic and International segments have offerings in six revenue categories. Computing and Mobile Phones, Consumer Electronics, Appliances, Entertainment, Services, and Other. The company has approximately 1,068 stores throughout its Domestic and International segments. It also have vendor store-within-a-store concepts to allow closer vendor partnerships and a higher quality customer experience. The company generates majority of its revenue from the Domestic segment.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: